Search Within

Steven Maron

  1. "Computational Oncology Service"
Formats
  1. Meeting Abstract (16)
  2. Journal Article (14)
Groups
  1. Computational Oncology Service (30)
  2. Department of Medicine (30)
  3. Epidemiology and Biostatistics (30)
  4. Gastrointestinal Oncology Service (30)
  5. Solid Tumor Oncology Division (30)
  6. GSK Faculty (29)

More Groups

People
  1. Nikolaus Schultz (29)
  2. Yelena Janjigian (22)
  3. Geoffrey Ku (18)
  4. David Ilson (16)
  5. Walid Chatila (15)
  6. David Solit (14)

More People

Years
  1. 2025 (2)
  2. 2024 (3)
  3. 2023 (9)
  4. 2022 (7)
  5. 2021 (4)
  6. 2020 (3)

More Years

Publications
  1. Journal of Clinical Oncology (11)
  2. Clinical Cancer Research (4)
  3. Cancer Research (2)
  4. JAMA Network Open (2)
  5. Annals of Oncology (1)
  6. Annals of Surgery (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (13)
  2. American Association for Cancer Research (6)
  3. American Medical Association (2)
  4. Elsevier Inc. (2)
  5. Oxford University Press (2)
  6. American Association of Neurological Surgeons (1)

More Publishers

Results (30)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Defining and targeting esophagogastric cancer genomic subsets with patient-derived xenografts
    Journal Article

    Moy, R. H.; Walch, H. S.; Mattar, M.; Chatila, W. K.; Molena, D.; Strong, V. E.; Tang, L. H.; Maron, S. B.; Coit, D. G.; Jones, D. R.; more...
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Walch, H. S.; Ptashkin, R.; Sabwa, S.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Prevalence of germline alterations on targeted tumor-normal sequencing of esophagogastric cancer
    Journal Article

    Ku, G. Y.; Kemel, Y.; Maron, S. B.; Chou, J. F.; Ravichandran, V.; Shameer, Z.; Maio, A.; Won, E. S.; Kelsen, D. P.; Ilson, D. H.; more...
    JAMA Network Open (2021)

    Fulltext@MSK | Save
  • Next-generation sequencing of 487 esophageal adenocarcinomas reveals independently prognostic genomic driver alterations and pathways
    Journal Article

    Sihag, S.; Nussenzweig, S. C.; Walch, H. S.; Hsu, M.; Tan, K. S.; Sanchez-Vega, F.; Chatila, W. K.; De La Torre, S. A.; Patel, A.; Janjigian, Y. Y.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • OncoTree: A cancer classification system for precision oncology
    Journal Article

    Kundra, R.; Zhang, H.; Sheridan, R.; Sirintrapun, S. J.; Wang, A.; Ochoa, A.; Wilson, M.; Gross, B.; Sun, Y.; Madupuri, R.; more...
    JCO Clinical Cancer Informatics (2021)

    Fulltext@MSK | Save
  • Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Millang, B. M.; Sabwa, S.; Chou, J. F.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • PD-L1 positive esophagogastric (EG) cancer is associated with distinct bacteria
    Meeting Abstract

    Maron, S. B.; Vanderbilt, C.; Sabwa, S.; Bowman, A.; Chatila, W. K.; Tang, L. H.; Strong, V. E.; Molena, D.; Jones, D. R.; Coit, D. G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial
    Journal Article

    Janjigian, Y. Y.; Maron, S. B.; Chatila, W. K.; Millang, B.; Chavan, S. S.; Alterman, C.; Chou, J. F.; Segal, M. F.; Simmons, M. Z.; Momtaz, P.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S.; Chou, J. F.; Gabler, A. R.; Simmons, M. Z.; Momtaz, P.; Shcherba, M.; Ku, G. Y.; Won, E.; Sanchez-Vega, F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S. B.; Chou, J. F.; Gabler, A.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save